on dRASTTM GN panel, we feature 4 drug mixes:

-Cefotaxime

-Cefotaxime / Clavulanic acid

-Ceftazidime

-Ceftazidime / Clavulanic acid

Based on CLSI decision matrix, dRASTTM will analyze the difference of MIC within these 4 drug mixes.

dRASTTM will therefore produce an ESBL result : Negative or Positive based on MIC differences

With 8 wells on Imipenem and 8 wells on Meropenem, we have a very clear MIC result which clearly indicates if the bacteria is resistant or not to carbapenem drugs. This also applies to Pseudomonas aeruginosa and Acinetobacter baumannii

dRASTTM does not feature an AmpC flag per se but with the 3 cephalosporin drugs present on GN panel (Cefepime, Cefotaxime, Ceftazidime), dRASTTM provides a clear susceptibility information regarding any resistance towards cephalosporin drugs.

For Staphylococcus aureus, Staphylococcus lugdunensis & Staphylococcus saprophyticus, we feature Oxacillin and Cefoxitin Screen which clearly indicates the difference between MRSA & MSSA.

For other Staphylococcus species, resistance is determined on Oxacillin MIC results. Cefoxitin Screen is less susceptible for these species.

Yes. If the strain is resistant to Erythromycin, in this case, dRASTTM considers the iCLI well on GP panel (mix of Erythromycin/Clindamycin). If any growth on iCLI well, iCLI appears positive and resistance to Clindamycin is detected

With 7 wells on Vancomycin, MIC result is produced on Vancomycin providing clear indication of VRE.

With 7 wells on Teicoplanin and 7 wells on Vancomycin, MIC result is produced on dRASTTM providing clear indication of GISA presence.